...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American journal of clinical pathology. >Clinicopathologic significance of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation: a collaborative study with Member Institutes of The Japanese Society of Thyroid Surgery.
【24h】

Clinicopathologic significance of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation: a collaborative study with Member Institutes of The Japanese Society of Thyroid Surgery.

机译：甲状腺内上皮胸腺瘤/癌表现出胸腺样分化的临床病理学意义：与日本甲状腺外科学会会员研究所的合作研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor having histopathologic features similar to those of squamous cell carcinoma of the thyroid and other organs and a more favorable prognosis. It is thought to originate from ectopic thymic tissue or embryonic thymic rest in or adjacent to the thyroid. We investigated clinicopathologic features of 25 cases of ITET/CASTLE. The sensitivity and specificity of the pathologic diagnosis of ITET/CASTLE by immunohistochemical staining with CD5, a marker of carcinoma of thymic origin, were 82% and 100%, respectively. The 5- and 10-year cause-specific survival rates were 90% and 82%, respectively. Nodal metastasis and tumor extension predict a worse prognosis. Of 22 patients who had curative surgery, 10 (45%) underwent adjuvant radiation therapy, and no locoregional recurrence was seen in any of them. This is the first study demonstrating the survival curve for patients with ITET/CASTLE. Our findings suggest that curative resection followed by radiation therapy may effectively prevent locoregional recurrence and CD5 immunostaining is useful for diagnosing ITET/CASTLE.
机译：表现出胸腺样分化（CASTLE）的甲状腺内上皮胸腺瘤（ITET）/癌是一种罕见的恶性肿瘤，其组织病理学特征与甲状腺及其他器官的鳞状细胞癌相似，且预后较好。人们认为它起源于甲状腺内或附近的异位胸腺组织或胚胎胸腺。我们调查了25例ITET / CASTLE的临床病理特征。用胸腺来源癌标志物CD5免疫组织化学染色对ITET / CASTLE进行病理诊断的敏感性和特异性分别为82％和100％。 5年和10年特定病因生存率分别为90％和82％。淋巴结转移和肿瘤扩展预后较差。在22例接受根治性手术的患者中，有10例（45％）接受了辅助放疗，并且均未见局部复发。这是第一项证明ITET / CASTLE患者生存曲线的研究。我们的发现表明，根治性切除术后放疗可有效预防局部复发，CD5免疫染色可用于诊断ITET / CASTLE。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号